down arrow

Orgenesis, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68619K2042
USD
0.75
0.00 (0.00%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.750.75

52 Week

0.005.89
Valuation
Technical
Day's Volume

CASH

150

Shareholding (Sep 2024)

FII

0.15%

Held by 7 FIIs

DII

96.94%

Held by 3 DIIs

Promoter

0.00%

How big is Orgenesis, Inc.?

22-Jun-2025

As of Jun 18, Orgenesis, Inc. has a market capitalization of 9.98 million, with net sales of 0.91 million and a net profit of -35.27 million over the last four quarters. The company reported shareholder's funds of -20.98 million and total assets of 14.55 million as of Dec 23.

Market Cap: As of Jun 18, Orgenesis, Inc. has a market capitalization of 9.98 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Orgenesis, Inc. reported net sales of 0.91 million and a net profit of -35.27 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company reported shareholder's funds of -20.98 million and total assets of 14.55 million.

Read More

What does Orgenesis, Inc. do?

22-Jun-2025

Orgenesis, Inc. is a biopharmaceutical company specializing in cell and gene therapy technologies and services. As of September 2024, it reported net sales of $0 million and a net loss of $9 million, with a market cap of $9.98 million.

Overview:<BR>Orgenesis, Inc. is a biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry, focused on developing, manufacturing, and processing technologies and services in the cell and gene therapy sector.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Sep 2024) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Sep 2024) <BR>Market cap: USD 9.98 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.60 <BR>Return on Equity: 121.55% <BR>Price to Book: -0.42 <BR><BR>Contact Details:<BR>Address: 20271 Goldenrod Ln, Germantown MD: 20876-4064 <BR>Tel: 1 480 6596404 <BR>Website: https://www.orgenesis.com/

Read More

Who are in the management team of Orgenesis, Inc.?

22-Jun-2025

As of March 2022, the management team of Orgenesis, Inc. is led by Ms. Vered Caplan as Chairperson and CEO, alongside independent directors Mr. Yaron Adler, Mr. Ashish Nanda, Mr. Mario Philips, Dr. David Sidransky, and Mr. Guy Yachin.

As of March 2022, the management team of Orgenesis, Inc. includes Ms. Vered Caplan, who serves as the Chairperson of the Board of Directors and Chief Executive Officer. The Board of Directors also comprises several independent directors: Mr. Yaron Adler, Mr. Ashish Nanda, Mr. Mario Philips, Dr. David Sidransky, and Mr. Guy Yachin.

Read More

Is Orgenesis, Inc. overvalued or undervalued?

25-Jun-2025

As of February 9, 2024, Orgenesis, Inc. is considered overvalued and has deteriorated to a "does not qualify" valuation grade due to negative financial metrics and a 1-year return of -71.41%, significantly underperforming its peers and the S&P 500.

As of 9 February 2024, the valuation grade for Orgenesis, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial metrics, including a price-to-book value of -0.42 and an EV to EBITDA ratio of -1.01. Furthermore, the EV to Sales ratio stands at 24.38, which is excessively high compared to industry norms.<BR><BR>In comparison with peers, Orgenesis, Inc. shows a stark contrast to Catalyst Biosciences, Inc., which is deemed expensive with a P/E ratio of 90.02, while other peers like Forte Biosciences, Inc. and Senti Biosciences, Inc. also do not qualify with negative valuation metrics. The company's recent stock performance has been dismal, with a 1-year return of -71.41%, significantly underperforming the S&P 500's 10.26% return in the same period. Overall, Orgenesis, Inc. is overvalued based on its current financial ratios and peer comparisons.

Read More

Is Orgenesis, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Orgenesis, Inc. is in a mildly bearish trend, with bearish indicators from the MACD, KST, and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -97.30%.

As of 11 September 2025, the technical trend for Orgenesis, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also indicate a bearish trend, while the monthly MACD shows a mildly bullish signal, suggesting some potential for recovery. The Bollinger Bands are bearish across both weekly and monthly time frames. Additionally, the On-Balance Volume (OBV) is mildly bearish on both weekly and monthly charts.<BR><BR>In terms of performance, Orgenesis has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -97.30% compared to the S&P 500's 12.22%, and a one-year return of -99.06% versus the S&P 500's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.60

stock-summary
Return on Equity

121.55%

stock-summary
Price to Book

-0.04

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Sep 2024)
Net Profit:
-9 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
400.0%
0%
400.0%
6 Months
-61.52%
0%
-61.52%
1 Year
-37.5%
0%
-37.5%
2 Years
-83.43%
0%
-83.43%
3 Years
-62.5%
0%
-62.5%
4 Years
-97.4%
0%
-97.4%
5 Years
-98.33%
0%
-98.33%

Orgenesis, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Orgenesis, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Orgenesis, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the weekly MACD and KST indicators, both of which are bearish. The daily moving averages also indicate a bearish trend, while the monthly MACD shows a mildly bullish signal, suggesting some potential for recovery. The Bollinger Bands are bearish across both weekly and monthly time frames. Additionally, the On-Balance Volume (OBV) is mildly bearish on both weekly and monthly charts. In terms of performance, Orgenesis has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -97.30% compared to the S&P 500's 12.22%, and a one-year return of -99.06% versus the S&P 500's 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-50.40%
EBIT Growth (5y)
-0.69%
EBIT to Interest (avg)
-29.27
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.60
Sales to Capital Employed (avg)
0.76
Tax Ratio
0.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.57%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-0.42
EV to EBIT
-0.94
EV to EBITDA
-1.01
EV to Capital Employed
-2.55
EV to Sales
24.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (2.91%)

Foreign Institutions

Held by 7 Foreign Institutions (0.15%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 50.00% vs 100.00% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 1.06% vs 6.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.10",
          "val2": "-3.40",
          "chgp": "-108.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "0.60",
          "chgp": "66.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "-4.50",
          "chgp": "82.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.30",
          "val2": "-9.40",
          "chgp": "1.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-21,962.50%",
          "val2": "-16,536.60%",
          "chgp": "-542.59%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -98.61% vs 1.41% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -431.97% vs 32.60% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "36.00",
          "chgp": "-98.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-53.30",
          "val2": "-5.60",
          "chgp": "-851.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.20",
          "val2": "1.70",
          "chgp": "29.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.00",
          "val2": "-1.10",
          "chgp": "9.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-64.90",
          "val2": "-12.20",
          "chgp": "-431.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-103,567.90%",
          "val2": "-209.30%",
          "chgp": "-10,335.86%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary
Sep'24
Jun'24
Change(%)
Net Sales
0.30
0.20
50.00%
Operating Profit (PBDIT) excl Other Income
-7.10
-3.40
-108.82%
Interest
1.00
0.60
66.67%
Exceptional Items
-0.80
-4.50
82.22%
Consolidate Net Profit
-9.30
-9.40
1.06%
Operating Profit Margin (Excl OI)
-21,962.50%
-16,536.60%
-542.59%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2024 is 50.00% vs 100.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 1.06% vs 6.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.50
36.00
-98.61%
Operating Profit (PBDIT) excl Other Income
-53.30
-5.60
-851.79%
Interest
2.20
1.70
29.41%
Exceptional Items
-1.00
-1.10
9.09%
Consolidate Net Profit
-64.90
-12.20
-431.97%
Operating Profit Margin (Excl OI)
-103,567.90%
-209.30%
-10,335.86%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -98.61% vs 1.41% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -431.97% vs 32.60% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Orgenesis, Inc. stock-summary
stock-summary
Orgenesis, Inc.
Pharmaceuticals & Biotechnology
Orgenesis Inc. is a biopharmaceutical company. The Company is developing, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates a point-of-care (POCare) cell therapy platform (POC). The POC platform develops Advanced Therapy Medicinal Products (ATMPs) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patient. The POC platform include a multitude of cell therapies, including autoimmune, oncologic, neurologic and metabolic diseases and other indications.
Company Coordinates stock-summary
Company Details
20271 Goldenrod Ln , GERMANTOWN MD : 20876-4064
stock-summary
Tel: 1 480 6596404
stock-summary
https://www.orgenesis.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."